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Conclusions. Less than10 lymphnodes retrieved after RCT is anegative prognostic factor, togetherwith local and regional response.
Further studies are necessary to conﬁrm these ﬁndings.
http://dx.doi.org/10.1016/j.rpor.2013.03.214
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Background. Esophageal cancer (EC) is the eighth most common cancer worldwide. The low survival and poor patient situation
has encouraged the development of multimodal treatments to improve prognosis and treatment tolerance. The role of the chemo
radiotherapy (CRT) has been discussed over the years, supported at present by many randomized studies Purpose: Evaluate the
results of EC according to therapeutic strategy.
Patients and methods. We retrospectively analyzed 52 EC patients with squamous cell carcinoma (SCC) and adenocarcinoma (AC)
treated with CRT between 1999 and 2012. All patients received CRT based on a platinum doublet and concurrent radiotherapy
(50.4Gy, 1.8Gy per fraction over 5–6 weeks or 45Gy, 1.8Gy per fraction over 5–6 weeks). After CRT, patients were subjected to
surgical resection, brachytherapy boost or clinical follow up.
Results. In total, 52 patients with SCC (82.7%) and AC (15.4%) were identiﬁed. Median age was 63 years (range 34–82). In the
diagnosis were 4% T1, 8% T2, 48% T3 and 25% T4 and the 70% had ganglionar metastases. Three types of treatments were
performed: exclusive CRT (57.7%) chemoradiotherapy followed by surgery (25%) or brachytherapy (17.3%). Toxicity grades 3–4
were presented in 25% of pts. The local ﬁrst relapse was as frequent as distant relapse (25% vs. 23%) With a 23 months median
follow-up, there are 15 alive without tumor, 35 deaths and 25 recurrences. Mean progression free survival was 11 months (95%
conﬁdence interval [IC]: 5–12). Mean OS was 23 month 95% IC (17–26). Five-year survival was 26% (95% conﬁdence interval [IC]:
13–41).
Conclusion. CRT is an effective treatment for locally advanced EC, and improvements the survival (OS and progression free
survival), although produces a highly toxicity that requires special cares including inpatient treatment.
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Introduction and objectives. the kidneys are some of the dose-limiting organs for radiotherapy to upper abdominal cancers.
Radiation-induced kidney damage happens after a long period of time. According to the latest recommendations the mean
dose for both kidneys should not exceed 18Gy. This study, analyzes radiation-induced kidney damage of patients (pts) with
gastric cancer treated with adjuvant radio-chemotherapy (RT-QT) in our center.
Material and methods. Retrospective cohort study of 102 pts with resectable locally advanced gastric cancer treated with adjuvant
RT-QT in our department from August 2003 until June 2012. The median age was 63.7 (range 36–84) and 63.7% were men. The
antrumandpylorus (56.8%)were themost frequent localization followedby gastric corpus (23.5%), fundus (4.9%) and gastroesoph-
ageal junction (10.7%). Median KPS score was 100% (70–100%). For the right kidney the median dose was 14.04Gy (range 2–29),
16.73Gy (1–34) for the left kidney and 15.65Gy (3–32) for both kidneys. Fluoropirimidines in monotherapy was the chemotherapy
used most frequently. All patients were treated with 3D conformal radiotherapy with a median dose of 45Gy (range 18–54)/1.8Gy
using photons of 18MV.
Results. The median follow-up was 36 months (6–101), 23 months for dead pts and 52 months for live pts. The median survival
was 52 months, 55% pts died. 21 pts had a median dose for both kidneys >18Gy and 4 pts developed a decreased glomerular
ﬁltration rate (<60%) and elevated creatinine levels (>1.4mg/dl). In the statistical analysis we did not ﬁnd any signiﬁcant impact
between the median dose for both kidneys and glomerular ﬁltration rate (p=0.198) and creatinine levels (p=0.762).
Conclusion. In our experience, we did not ﬁnd any relationship between the radiation dose received by the kidneys and renal
dysfunction. However, our study had a short follow up and we have to evaluate the dysfunction after 10 years.
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